Vascular Biogenics Ltd. (VBLT)

NASDAQ: VBLT · IEX Real-Time Price · USD
1.21
0.00 (0.00%)
Jan 28, 2022 3:00 PM EST - Market open
Market Cap83.85M
Revenue (ttm)777,000
Net Income (ttm)-28.07M
Shares Out69.30M
EPS (ttm)-0.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume73,423
Open1.22
Previous Close1.21
Day's Range1.19 - 1.25
52-Week Range1.13 - 3.17
Beta1.06
AnalystsBuy
Price Target5.50 (+354.5%)
Earnings Daten/a

About VBLT

Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications in Israel and the United States. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovar...

IndustryBiotechnology
IPO DateOct 1, 2014
CEODror Harats
Employees38
Stock ExchangeNASDAQ
Ticker SymbolVBLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for VBLT stock is "Buy." The 12-month stock price forecast is 5.50, which is an increase of 354.55% from the latest price.

Price Target
$5.50
(354.55% upside)
Analyst Consensus: Buy

News

VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-trea...

1 week ago - GlobeNewsWire

VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat mal...

3 weeks ago - GlobeNewsWire

VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program

VBL is among only 9% of companies across industries selected by the EIC Accelerator

1 month ago - GlobeNewsWire

What Makes Vascular Biogenics (VBLT) a New Buy Stock

Vascular Biogenics (VBLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 10.00% and -0.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Conference Call and Webcast at 8:30 a.m. ET Today

2 months ago - GlobeNewsWire

Will Vascular Biogenics (VBLT) Report Negative Q3 Earnings? What You Should Know

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

VBL Therapeutics to Report Third Quarter Financial Results on November 15

TEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VB L Therape u tics  (Nasdaq: VBLT ), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant so...

2 months ago - GlobeNewsWire

VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the...

Amos Ron to Retire as CFO and Will Continue to Serve as Corporate Secretary, Advisor to VBL Amos Ron to Retire as CFO and Will Continue to Serve as Corporate Secretary, Advisor to VBL

3 months ago - GlobeNewsWire

VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase...

TEL AVIV, Israel, Sept. 17, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced that the independent Data Safety Monitoring Committee (DSMC) of the ongoing OVAL Phase 3 registration...

4 months ago - GlobeNewsWire

VBL Therapeutics to Present at Upcoming Conferences

TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences:

4 months ago - GlobeNewsWire

VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produ...

TEL AVIV, Israel, Aug. 30, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced enrollment of new patients in VB-111 studies in the Unites States will resume immediately following au...

4 months ago - GlobeNewsWire

Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -20.00% and -48.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

VBL Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Conference Call and Webcast at 8:30 a.m. EDT Today

5 months ago - GlobeNewsWire

Will Vascular Biogenics (VBLT) Report Negative Q2 Earnings? What You Should Know

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

VBL Therapeutics to Report Second Quarter Financial Results on August 16

TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before marke...

5 months ago - GlobeNewsWire

VBL Therapeutics Appoints Marc Kozin as Chairman of its Board of Directors

TEL AVIV, Israel, July 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the planned elevation of Marc Kozin as chairman of the company's board of directors. Bennett Shapiro, ...

6 months ago - GlobeNewsWire

VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors

TEL AVIV, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7, 2021. ...

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Biogenics Ltd. - VBLT

NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vascular Biogenics Ltd. ("VBL" or the "Company") (NASDAQ: VBLT).

7 months ago - PRNewsWire

VBL Therapeutics Shares Drop As Pending Clearance Of New Batches Cancer Gene Therapy Hit Recruitment In Ovarian Cance...

The FDA notified VBL Therapeutics Ltd (NASDAQ: VBLT) that clearance of new VB-111 batches for use in the U.S. is currently pending, as review by the Chemistry, Manufacturing, and Controls (CMC) group is...

7 months ago - Benzinga

VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Regi...

TEL AVIV, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced a primary endpoint amendment in the OVAL Phase 3 registration-enabling study of VB-111. The clinical t...

7 months ago - GlobeNewsWire

VBL Therapeutics to Provide an Update on the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer at ...

TEL AVIV, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of VB-111 in...

8 months ago - GlobeNewsWire

Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and -7.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

VBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Conference Call and Webcast at 8:30 a.m. EDT Today

8 months ago - GlobeNewsWire

Vascular Biogenics's Earnings: A Preview

Vascular Biogenics (NASDAQ:VBLT) announces its next round of earnings this Tuesday, May 11. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings announcement.

8 months ago - Benzinga